Evidence map›Paper›PMID 31602375›Full record

ArticleGastrointestinal tumors2019

Primary Jejunal Gastrointestinal Stromal Tumor: Diagnosis Delay of 3 Years but Successful Management in Early Stage (II) by Surgery and Adjuvant Therapy.

Ferdous Ara Begum, Md Arifur Rahman, Hashim Rabbi, Golam Mostofa, Qamruzzaman Chowdhury

Open access · goldAbstract readCase Reports
In one paragraph

Article in Gastrointestinal tumors, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Solutions to the Drawbacks of Photothermal and Photodynamic Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Ferdous Ara BegumDepartment of Medical Oncology, National Institute of Cancer Research and Hospital, Dhaka, Bangladesh.
Md Arifur RahmanDepartment of Oncology, Bangladesh Specialized Hospitals, Dhaka, Bangladesh.
Hashim RabbiDepartment of Surgery, BRB Hospitals Limited, Dhaka, Bangladesh.
Golam MostofaAnowara Medical Services, Dhaka, Bangladesh.
Qamruzzaman ChowdhuryDepartment of Oncology, Bangladesh Specialized Hospitals, Dhaka, Bangladesh.
National Institute of Cancer Research and Hospital · BDSquare Hospitals · BD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the digestive system, mesenchymal origin of tumors is quite rare; in general, they are recognized as gastrointestinal stromal tumors (GISTs). The incidence of GISTs is very low (2 in 100,000), while jejunal GISTs are extremely rare, accounting for 0.1-3% of all gastrointestinal (GI) tumors. Small intestinal GISTs are the second most common (25%) site in the GI tract, usually occurring in the duodenum. We present the case of a 62-year-old Bangladeshi female with a history of GI bleeding 3 years earlier; the cause of the bleeding had not been found despite extensive investigations. In the meantime, the patient had developed occasional abdominal pain and lumpy feelings in the right side of the abdomen without any GI bleeding. Exploratory laparotomy was carried out in view of a small intestinal mesenteric mass in a computed tomography scan. On midline incision there was a 6 × 6 cm mass in the antimesenteric border of the jejunum approximately 30 cm from the duodenojejunal flexure, which was resected followed by anastomosis. The presentation of GISTs ranges from asymptomatic to mild abdominal pain and mass (5-50%) and mechanical obstruction (5%) as well as hemorrhage - perforation having rarely been reported (0.8%) - making the diagnosis difficult. Exophytic growth of these tumors has been noted in 18-30% of cases. In view of intermediate risk of malignancy, the patient was started with adjuvant imatinib 400 mg once daily due to probability of disease recurrence (24%).

Indexed as

Adjuvant therapyGastrointestinal stromal tumorImatinibJejunumPrimary treatment

Identifiers

PMID31602375
PMCPMC6738160
OpenAlexW2935367507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.